Depression can make everything feel simplified in the worst possible way. Energy is gone. Hope feels distant. Ordinary tasks become heavy. Yet the clinical picture beneath those symptoms may be more complicated than it first appears.
Bipolar depression and major depressive disorder can look remarkably similar during a depressive episode. Both can involve low mood, exhaustion, guilt, changes in sleep or appetite, slowed thinking, and thoughts that life may not be worth living. The difference is not a matter of labels alone. It affects the questions we ask, the history we need to understand, and how carefully we consider any next step, including ketamine.
At The Mood Center, we believe a diagnosis should be treated as a working understanding of a whole person, not a shortcut. For people seeking mental health services in Columbia, that means making room for the details that can be easy to miss when depression has taken over the foreground.
When depression is part of a larger mood pattern
Major depression, sometimes called unipolar depression, involves depressive episodes without a history of mania or hypomania. Bipolar disorders also include depressive episodes, but they are defined by periods of elevated, expansive, or unusually irritable mood and changes in energy or activity.
Mania is often visible in its intensity. A person may sleep very little, speak rapidly, feel unusually powerful or driven, take major risks, spend impulsively, or lose touch with reality. Hypomania can be quieter. It may feel productive, social, energized, or even welcome at the time. That is one reason it is so often overlooked.
The National Institute of Mental Health describes bipolar disorder as involving shifts in mood, energy, and activity that can interfere with daily life, while depressive symptoms may occupy substantial parts of the illness experience. Information on mood disorders can be a useful starting point, but a real assessment requires more than matching symptoms to a checklist (National Institute of Mental Health, n.d.).
A person may come in asking about depression and only later remember a week of sleeping three hours a night without fatigue, a period of unusually fast decisions, or an episode that loved ones saw very differently. Those details matter. So does family history. So do prior medication responses, substance use, trauma history, medical conditions, and the timing of symptoms across years rather than days.
Why a bipolar-spectrum assessment cannot be rushed
Depression is painful, and the wish for relief is understandable. Still, speed should not replace discernment. A careful conversation can help us distinguish a depressive episode that stands alone from one occurring within a bipolar-spectrum condition.
We may ask about:
Past periods of reduced need for sleep, increased activity, or unusually elevated or irritable mood
Impulsive spending, sexual behavior, substance use, driving, or other risks that felt out of character
Episodes of racing thoughts, pressured speech, or feeling impossible to slow down
Family history of bipolar disorder, suicide attempts, or psychiatric hospitalization
Previous antidepressant experiences, including agitation, activation, or abrupt mood shifts
The role of alcohol, cannabis, stimulants, or other substances in changes of mood and sleep
These questions are not an interrogation. They are a way of protecting the complexity of your story. Bipolar disorder also carries a serious suicide risk, particularly during depressive and mixed mood states, which is why a thorough assessment includes direct, compassionate discussion of safety. Research on suicide risk factors in bipolar disorder underscores the importance of recognizing clinical history and current risk clearly (Schaffer et al., 2015).
What diagnosis changes before discussing ketamine
We offer ketamine care for bipolar disorder when it is clinically appropriate, but ketamine is not a universal answer and psychiatric use of ketamine is off-label. The decision begins with diagnosis, safety, and whether the treatment fits the person in front of us.
Ketamine has been studied in both unipolar and bipolar depression, yet research findings do not erase the importance of individual evaluation. A large pooled analysis found that outcomes varied across patients and examined the clinical factors that may shape response, reminding us that averages in research do not determine an individual course of care. Patient-level research on clinical moderators makes that point especially clear (Price et al., 2022).
For a person with bipolar depression, we consider the larger treatment plan. Mood stability, current symptoms, medication history, substance-use concerns, medical history, support at home, and the possibility of activation or changing mood states all deserve attention. We also discuss what monitoring would look like and what support may be needed between visits.
Our ketamine and bipolar care is grounded in that careful clinical context. It is not built around asking whether someone is distressed enough to try something new. It is built around understanding what kind of depression they are experiencing, and what responsible care requires.
The research is meaningful, not a promise
Ketamine is a dissociative anesthetic that has also been investigated for depressive episodes. In studies of major depressive episodes, ketamine has been compared with other interventions, including electroconvulsive therapy, but study populations, treatment settings, and clinical circumstances differ. A systematic review comparing ketamine and ECT illustrates both the seriousness of this research and the need to avoid reducing treatment decisions to a single headline (Rhee et al., 2022).
We also take questions about cognition seriously. Dissociation, altered perception, fatigue, and other short-term experiences can occur around treatment. A systematic review examining cognition in unipolar and bipolar depression found a limited and evolving evidence base, rather than a simple conclusion that applies equally to everyone. The review of cognition findings supports the need for individualized monitoring and informed conversation (Vaccarino et al., 2022).
For some people, an IV ketamine therapy discussion may be appropriate. For others, it may not be. We may also need to focus first on medication management, sleep stabilization, substance-use support, psychotherapy, or a higher level of care. A thoughtful “not yet” can be as clinically important as a yes.
Ketamine, IM treatment, and other options are not interchangeable
The form of treatment matters, but it comes after the diagnostic work. We offer IV ketamine and IM ketamine injections, each with clinical considerations that should be discussed in context.
We also offer SPRAVATO®, an esketamine nasal spray administered under supervision. It is a distinct medication and experience, with its own eligibility, monitoring, and coverage considerations. It should not be treated as interchangeable with IV or IM ketamine simply because the names are related. You can learn more about our FDA-approved ketamine nasal spray and the questions that may arise during a consultation.
TMS is another service we offer. It is FDA-cleared, but it too deserves an individual discussion rather than a broad assumption about what it may fit. Diagnosis is the beginning of that discussion, not an administrative detail before it.
Addressing two common fears
“What if I have been told I only have depression?”
That concern is valid. A prior diagnosis may be accurate, or it may need revisiting as new information comes into view. We do not assume that a label from years ago tells the full story today. We listen for patterns, ask about episodes that may have seemed normal at the time, and consider what has changed.
“What if I need help now?”
You do not have to wait until your story is perfectly organized to ask for care. We can begin with what you know. If you are in immediate danger, have a plan to harm yourself, or cannot stay safe, call or text 988 or use the 988 Suicide & Crisis Lifeline chat option. For an emergency, call 911 or go to the nearest emergency department (988 Suicide and Crisis Lifeline, n.d.).
Frequently asked questions
Can symptoms alone tell me whether I have bipolar depression?
Usually not. The depressive symptoms overlap substantially. The distinction often depends on lifetime mood history, shifts in energy and behavior, family history, and information from people close to you when appropriate.
Does ketamine work for every person with bipolar depression?
No. Ketamine may be considered for bipolar disorder in an appropriate clinical setting, but it is not suitable for every person and no treatment outcome can be predicted in advance. A full assessment helps determine whether it belongs in your care plan.
Should I stop my current medication before an evaluation?
Do not change prescribed medication on your own. Bring a complete list of medications, supplements, and substances you use so we can have an informed conversation about safety and coordination of care.
What should I bring to a consultation?
If possible, bring prior diagnoses, medication history, records of hospitalizations or past treatment, and notes about periods of unusually high energy or reduced sleep. You can also review our ketamine FAQs before your visit.
Key takeaways
Bipolar depression and major depression can feel alike from the inside. Their differences often emerge through time, pattern, and careful questions.
A bipolar-spectrum assessment is not meant to delay care. It is meant to make care safer, clearer, and more responsive to the full reality of your life. If you are living with depressive symptoms and wondering whether bipolar disorder may be part of the picture, we invite you to reach out to The Mood Center. We can begin with a conversation, at a pace that respects both urgency and care.
Medical disclaimer
This article is for educational purposes and is not medical advice, diagnosis, or a substitute for emergency care. Treatment decisions should be made with a qualified clinician who understands your medical and psychiatric history.
Works Cited
1. National Institute of Mental Health. Health Topics. https://www.nimh.nih.gov/health/topics
2. Schaffer A, et al. A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder. https://pubmed.ncbi.nlm.nih.gov/26175498/
3. Price RB, et al. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. https://pubmed.ncbi.nlm.nih.gov/36071111/
4. Rhee TG, et al. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. https://pubmed.ncbi.nlm.nih.gov/36260324/
5. Vaccarino SR, et al. The Effects of Ketamine on Cognition in Unipolar and Bipolar Depression: A Systematic Review. https://pubmed.ncbi.nlm.nih.gov/34985832/
6. 988 Suicide and Crisis Lifeline. https://988lifeline.org/
Disclaimer
This article is for educational purposes only and is not a substitute for individualized evaluation, diagnosis, or treatment from a qualified healthcare professional.
